Darbepoetin alfa biosimilar - CJ Healthcare

Drug Profile

Darbepoetin alfa biosimilar - CJ Healthcare

Alternative Names: CJ-40001

Latest Information Update: 20 Jun 2016

Price : $50

At a glance

  • Originator CJ HealthCare
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Anaemia

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 01 Jan 2016 Darbepoetin alfa biosimilar - CJ Healthcare is available for worldwide licensing as of 01 Jan 2016. www.cjp.co.kr
  • 24 Dec 2015 Phase-II clinical trials in Anaemia in South Korea (unspecified route) (CJ Healthcare pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top